Khiron Life Sciences (STU:4KH) Other Stockholders Equity: €0.00 Mil (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Khiron Life Sciences Other Stockholders Equity?

Khiron Life Sciences STU:4KH Other Stockholders Equity is €0.00 Mil as of Sep. 2022.

Khiron Life Sciences's Other Stockholders Equity for the quarter that ended in Sep. 2022 was €0.00 Mil.

Khiron Life Sciences's quarterly Other Stockholders Equity increased from Mar. 2022 (€-0.00 Mil) to Jun. 2022 (€-0.00 Mil) and increased from Jun. 2022 (€-0.00 Mil) to Sep. 2022 (€0.00 Mil).

Khiron Life Sciences's annual Other Stockholders Equity declined from Dec. 2019 (€0.00 Mil) to Dec. 2020 (€-0.00 Mil) but then increased from Dec. 2020 (€-0.00 Mil) to Dec. 2021 (€0.00 Mil).

Khiron Life Sciences Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Khiron Life Sciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Khiron Life Sciences Other Stockholders Equity Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 0.00

Khiron Life Sciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.00 Mil mean?
Khiron Life Sciences (STU:4KH) has a Other Stockholders Equity of €0.00 Mil as of Sep. 2022. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Khiron Life Sciences and its competitors.
Is Khiron Life Sciences' Other Stockholders Equity too high?
Khiron Life Sciences' current Other Stockholders Equity is €0.00 Mil.
How does Khiron Life Sciences' Other Stockholders Equity compare to ZTS and CTLT?
Khiron Life Sciences' Other Stockholders Equity of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Khiron Life Sciences and its competitors. Khiron Life Sciences's current Other Stockholders Equity is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Khiron Life Sciences stock overvalued right now?
Khiron Life Sciences (STU:4KH) has a current Other Stockholders Equity of €0.00 Mil. The current Other Stockholders Equity is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Khiron Life Sciences (STU:4KH), the current Other Stockholders Equity is €0.00 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Khiron Life Sciences Business Description

Address 2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.